Xspray Pharma Ab Stock Current Ratio
| XSPRAY Stock | SEK 42.10 0.10 0.24% |
XSpray Pharma AB fundamentals help investors to digest information that contributes to XSpray Pharma's financial success or failures. It also enables traders to predict the movement of XSpray Stock. The fundamental analysis module provides a way to measure XSpray Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XSpray Pharma stock.
XSpray |
XSpray Pharma AB Company Current Ratio Analysis
XSpray Pharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current XSpray Pharma Current Ratio | 26.45 X |
Most of XSpray Pharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XSpray Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, XSpray Pharma AB has a Current Ratio of 26.45 times. This is much higher than that of the Healthcare sector and 277.86% higher than that of the Biotechnology industry. The current ratio for all Sweden stocks is notably lower than that of the firm.
XSpray Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XSpray Pharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XSpray Pharma could also be used in its relative valuation, which is a method of valuing XSpray Pharma by comparing valuation metrics of similar companies.XSpray Pharma is currently under evaluation in current ratio category among its peers.
XSpray Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Operating Margin | (116.51) % | |||
| Current Valuation | 1.16 B | |||
| Shares Outstanding | 22.68 M | |||
| Shares Owned By Insiders | 47.42 % | |||
| Shares Owned By Institutions | 27.60 % | |||
| Price To Book | 2.35 X | |||
| Price To Sales | 1,206 X | |||
| Gross Profit | 656 K | |||
| EBITDA | (87.82 M) | |||
| Net Income | (96.7 M) | |||
| Cash And Equivalents | 192.85 M | |||
| Cash Per Share | 12.79 X | |||
| Total Debt | 1.19 M | |||
| Debt To Equity | 2.80 % | |||
| Current Ratio | 26.45 X | |||
| Book Value Per Share | 24.95 X | |||
| Cash Flow From Operations | (51.61 M) | |||
| Earnings Per Share | (5.18) X | |||
| Target Price | 135.0 | |||
| Number Of Employees | 26 | |||
| Beta | 0.97 | |||
| Market Capitalization | 1.45 B | |||
| Total Asset | 622.9 M | |||
| Net Asset | 622.9 M |
About XSpray Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XSpray Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XSpray Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XSpray Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in XSpray Stock
XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.